Allovir, Inc.

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support its pipeline of allogeneic, off-the-shelf virus-specific T cell therapies during the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition taking place virtually December 5 – 8, 2020.

AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting

Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral Infections Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral Infections 

Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients

Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept Trials Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept Trials

AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer

CAMBRIDGE, Mass., Sept.  02, 2020  (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020.

AlloVir Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., Aug.  25, 2020  (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020 at 5:00 p.m. ET.

AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Xerox

Compass Diversified Holdings

eHealth

F5 Networks

IQVIA Hlds

QuidelOrtho Corp

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys at Allovir, Xerox And Many More

Stock of virus therapy biotech up more than 70% in just a few days

AlloVir Shares Skyrocket Following IPO

CAMBRIDGE, Mass., Aug.  03, 2020  (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offering of 18,687,500 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase up to 2,437,500 additional shares of common stock, at a public offering price of $17.00 per share, before underwriting discounts and commissions. All of the common stock was offered by AlloVir. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AlloVir, were approximately $317.7 million. AlloVir’s common stock is listed on The Nasdaq Global Market under the ticker symbol “ALVR.”

AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

AlloVir Inc.  said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share.

AlloVir prices upsized IPO at $17, to be valued at over $1 billion

CAMBRIDGE, Mass., July  30, 2020  (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offering of 16,250,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions. AlloVir’s common stock is expected to begin trading on The Nasdaq Global Market on July 30, 2020 under the ticker symbol “ALVR.” All of the common stock is being offered by AlloVir. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AlloVir, are expected to be $276.25 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on August 3, 2020, subject to satisfaction of customary closing conditions. AlloVir has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of AlloVir’s common stock at the initial public offering price, less underwriting discounts and commissions.

AlloVir Announces Pricing of Upsized Initial Public Offering

News for Allovir, Inc. Stock (ALVR)